|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
1.250 -0.020 (-1.575%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 1,151,145 | -9.904% | 1,277,682 | 1,165,155 | 1,024,270 | 950,007 |
| Cost of Sales | (509,626) | 1.090% | (504,131) | (483,893) | (473,625) | (414,138) |
| Gross Profit | 641,519 | -17.068% | 773,551 | 681,262 | 550,645 | 535,869 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (40,933) | -33.878% | (61,905) | (46,418) | (18,771) | (11,829) | |
| Profit / (Loss) before Taxation | 414,057 | -5.554% | 438,408 | 439,323 | 331,298 | 314,094 | |
| Taxation | (91,390) | 10.699% | (82,557) | (85,160) | (66,505) | (58,738) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,333 | 51.088% | 2,206 | 4,012 | 3,337 | 74 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 326,000 | -8.953% | 358,057 | 358,175 | 268,130 | 255,430 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (24,938) | 31.225% | (19,004) | (19,171) | (12,250) | (11,732) |
| Depreciation & Amortisation | 83,893 | 26.326% | 66,410 | 57,545 | 56,008 | 53,375 |
| Directors' Emoluments | 2,973 | -3.755% | 3,089 | 9,667 | 10,861 | 8,777 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 21.740 | -9.000% | 23.890 | 23.920 | 17.360 | 16.210 |
| DPS (cts) | 7.262 | -- | 7.666 | 6.513 | 9.702 | 5.270 |
| Dividend Payout Ratio (%) | 33.405% | -- | 32.087% | 27.226% | 55.888% | 32.509% |
| Cash flow per share ($) | 0.226 | -- | 0.290 | 0.263 | 0.196 | 0.175 |
| NBV per share ($) | 1.903 | -- | 1.763 | 1.589 | 1.433 | 1.301 |
| Remarks: | Real time quote last updated: 08/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 493,046,000 |
| %Change | 92.640% |
| EPS / (LPS) | RMB 0.329 |
| NBV Per Share (¥) | RMB 2.178 |